<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For re-publication" DOI="10.1002/14651858.CD006695.pub2" GROUP_ID="ENDOC" ID="182306040417002214" MERGED_FROM="" MODIFIED="2009-05-05 10:28:13 +0200" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="R_I_08_1" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.3">
<COVER_SHEET MODIFIED="2009-05-05 10:19:07 +0200" MODIFIED_BY="Gudrun Paletta">
<TITLE>Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy</TITLE>
<CONTACT>
<PERSON ID="780C13E082E26AA201650CEA1FD8D0FA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carlos César</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lopes de Jesus</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>caceloje@gmail.com</EMAIL_1>
<EMAIL_2>caceloje@uol.com.br</EMAIL_2>
<URL/>
<MOBILE_PHONE>+ 55 11 5576 4228</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine and Therapeutics Discipline</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo / Escola Paulista de Medicina</ORGANISATION>
<ADDRESS_1>Rua Pedro de Toledo, 598</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 04039-001</ZIP>
<REGION>Vila Clementino</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+ 55 11 5575 2970</PHONE_1>
<PHONE_2>+ 55 11 5579 0469</PHONE_2>
<FAX_1>+ 55 11 5579 0469</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-05-05 10:18:28 +0200" MODIFIED_BY="Gudrun Paletta">
<PERSON ID="780C13E082E26AA201650CEA1FD8D0FA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carlos César</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lopes de Jesus</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>caceloje@gmail.com</EMAIL_1>
<EMAIL_2>caceloje@uol.com.br</EMAIL_2>
<URL/>
<MOBILE_PHONE>+ 55 11 5576 4228</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine and Therapeutics Discipline</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo / Escola Paulista de Medicina</ORGANISATION>
<ADDRESS_1>Rua Pedro de Toledo, 598</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 04039-001</ZIP>
<REGION>Vila Clementino</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+ 55 11 5575 2970</PHONE_1>
<PHONE_2>+ 55 11 5579 0469</PHONE_2>
<FAX_1>+ 55 11 5579 0469</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5183" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Álvaro</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Atallah</LAST_NAME>
<SUFFIX>MD, PhD.</SUFFIX>
<POSITION>Professor of Emergency Medicine and Evidence-Based Medicine, Director of Brazilian Cochrane Centre</POSITION>
<EMAIL_1>atallahmbe@uol.com.br</EMAIL_1>
<EMAIL_2>cochrane.dmed@epm.br</EMAIL_2>
<URL/>
<MOBILE_PHONE>+55 11 8173 0404</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo / Escola Paulista de Medicina</ORGANISATION>
<ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1>
<ADDRESS_2>Vila Clementino</ADDRESS_2>
<CITY>São Paulo</CITY>
<ZIP>CEP 04039-001</ZIP>
<REGION>SP</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5575 2970</PHONE_1>
<PHONE_2>+55 11 5571 4721</PHONE_2>
<FAX_1>+55 11 5579 0469</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14753" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Orsine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Valente</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>orsineops@zaz.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo / Escola Paulista de Medicina</ORGANISATION>
<ADDRESS_1>Rua Pedro de Toledo, 598</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 04039-001</ZIP>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14973" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Virginia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fernandes Moça Trevisani</LAST_NAME>
<SUFFIX/>
<POSITION>Titular Professor/Guidance Counsellor Professor</POSITION>
<EMAIL_1>vmoca@uol.com.br</EMAIL_1>
<EMAIL_2>cochrane.dmed@epm.br</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Rheumatology/Internal Medicine and Therapeutics</DEPARTMENT>
<ORGANISATION>UNISA (Santo Amaro University)/UNIFESP (Paulista Medicine School)</ORGANISATION>
<ADDRESS_1>Rua Marie Satzke 119</ADDRESS_1>
<ADDRESS_2/>
<CITY>Jardim Marajoara</CITY>
<ZIP>04664-150</ZIP>
<REGION>Sao Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 55752970</PHONE_1>
<PHONE_2>+55 11 38314161</PHONE_2>
<FAX_1>+55 11 55790496</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-08 10:53:29 +0100" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2009-05-05 10:19:07 +0200" MODIFIED_BY="Gudrun Paletta">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-05 10:18:57 +0200" MODIFIED_BY="Gudrun Paletta">
<DATE DAY="7" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>- Reference Halliwell 1999 corrected with Campos 1996;</P>
<P>- Wrong reference deleted: Balasubramanyam 2003;</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-05-05 10:12:15 +0200" MODIFIED_BY="Gudrun Paletta"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-03-25 12:12:40 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY MODIFIED="2008-11-08 10:54:16 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2008-11-08 10:54:16 +0100" MODIFIED_BY="Gudrun Paletta">Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy</TITLE>
<SUMMARY_BODY>
<P>Diabetic retinopathy or eye disease is the leading cause of blindness in developed countries. Laser therapy currently is the primary means in the treatment of diabetic retinopathy. It nevertheless is a procedure which destroys important cells in the eye. There are theories that so-called free radicals (substances which are thought to be harmful to body tissues) might be influenced by new medications to prevent or slow down vision loss in people with diabetes. Preliminary studies with vitamin C and 'superoxide dismutase' suggest that they may have an important role in treatment of diabetic retinopathy.<BR/>Unfortunately, our thorough search to detect sound clinical studies with these compounds did not identify any relevant trial. Future updates of this review may find important new information about this potentially hopeful new therapy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>There is increasing evidence that diabetic retinopathy is caused by the action of free radicals. Radical scavengers like vitamin C and superoxide dismutase (SOD) may influence the outcome and progression of diabetic retinopathy, but no systematic review of the literature has been published to examine this hypothesis. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The aim of the current research was to review the literature in a standard systematic way in order to assess the effects of vitamin C and superoxide dismutase on diabetic retinopathy in methodologically robust trials.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We tried to obtain studies from computerised searches of MEDLINE, EMBASE, CINAHL, Web of Science and <I>The Cochrane Library</I>.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Only randomized clinical trials (RCTs) that evaluated the effect of vitamin C, superoxide dismutase or both in the treatment of diabetic retinopathy were considered. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently read all abstracts, titles or both and wanted to assess risk of bias and to perform data extraction. Discrepancies were planned to be resolved by consensus or by the judgement of a third author.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>A total of 241 publications were identified by the electronic searches. Of these, 28 were identified as potentially containing information about the treatment of patients with diabetic retinopathy using vitamin C or SOD and were read in full. No trial evaluated the treatment of diabetic retinopathy with vitamin C or SOD.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>No research to date has adequately examined the treatment of diabetic retinopathy with vitamin C or SOD in such a way as to indicate whether this form of intervention has a significant impact on the progress of this clinical condition. The potential role of these substances in the treatment of diabetic retinopathy remains open to debate, and it is suggested that future research focusing on patient-oriented outcomes should address this important issue.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-03-25 12:12:40 +0100" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2009-03-25 12:12:40 +0100" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2009-02-17 12:13:27 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. A consequence of this is chronic hyperglycaemia (that is elevated levels of plasma glucose) with disturbances of carbohydrate, fat and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy and neuropathy. The risk of cardiovascular disease is increased. For a detailed overview of diabetes mellitus, please see under 'Additional information' in the information on the Metabolic and Endocrine Disorders Group in <I>The Cochrane Library </I>(see 'About', 'Cochrane Review Groups (CRGs)'). For an explanation of methodological terms, see the main glossary in <I>The Cochrane Library</I>.<BR/>
</P>
<P>During the first two decades of the disease, nearly all patients with type 1 diabetes and more than 60% of patients with type 2 diabetes develop retinopathy. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 3.6% type 1 diabetes and 1.6% type 2 diabetes patients were legally blind. In the younger-onset group, 86% of blindness was attributable to diabetic retinopathy. In the older-onset group, one-third of legal blindness was associated with diabetic retinopathy (<LINK REF="REF-Klein-1984" TYPE="REFERENCE">Klein 1984</LINK>).</P>
<P>Diabetic retinopathy is detected clinically by the presence of visible ophthalmoscopic retinal microvascular lesions in an individual with diabetes mellitus. Retinopathy can be classified as non proliferative (NPDR) and proliferative diabetic retinopathy (PDR). NPDR is again divided into NPDR with maculopathy, NPDR without maculopathy and pre-proliferative retinopathy.<BR/>NPDR indicates progressive ischemia in the retina and an increased risk for the development of PDR and blindness. The prominent features of NPDR include microaneurysms, dot or blot haemorrhages, venous abnormalities, hard yellow exudates, intraretinal microvascular abnormalities, and cotton wool spots. Maculopathy is defined as the presence of oedema, haemorrhages, exudates, retinal thickening within five mm of the fovea, with or without visual loss or a combination of these factors. Pre-proliferative diabetic retinopathy is the stage before the onset of neovascularization and is characterized by extensive retinal haemorrhages, marked venous beading, numerous cotton wool spots or retinal infarcts, intra-retinal microvasculature abnormalities and marked retinal ischemia as evidenced by capillary drop-outs in the fundus fluorescein angiogram. Proliferative diabetic retinopathy is characterized by retinal new vessels, fibrous tissue, pre-retinal haemorrhage, vitreous haemorrhage, vitreoretinal traction and localized retinal detachment (Balasubramanyam 2003).<BR/>Laser photocoagulation is the primary means by which ophthalmologists control the progression of macular edema and neovascularization. Since it is still an invasive procedure destroying the retinal cells, pharmacotherapeutic approaches were developed to prevent or regress retinal lesions in diabetic people (<LINK REF="REF-Balasubramanyam-2002" TYPE="REFERENCE">Balasubramanyam 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-03-25 12:12:40 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Studies revealed the retina is high in polyunsaturated fatty acids and has the highest glucose oxidation and oxygen uptake of any tissue, thus being extremely susceptible to increased oxidative stress. Impaired activities of antioxidant defence enzymes such as superoxide dismutase (SOD) appear to be one of the possible sources of oxidative stress in diabetes. Recent evidence also points to reactive oxygen species (ROS) in the mitogenic cascade initiated by the tyrosine kinase receptors of several growth factors, including vascular endothelial growth factor (VEGF) (<LINK REF="REF-Balasubramanyam-2002" TYPE="REFERENCE">Balasubramanyam 2002</LINK>).<BR/>In 1969, McCord and Fridovich reported on an enzyme capable of removing the superoxide radical catalytically. They named this enzyme superoxide dismutase. There are three types of SOD: Copper-zinc SOD (CuZn-SOD), manganese SOD (Mn-SOD) and iron SOD (Fe-SOD) - being present only in bacteria, algae and higher plants. The discovery of SOD enzymes led to two important facts: 1. the superoxide theory of oxygen toxicity (which proposes that superoxide is a major factor in oxygen toxicity and that SODs are an essential defence against it) and 2. the introduction of the concept of antioxidants (any substance that, when present at low concentrations compared with those of an oxidizable substrate, significantly delays or prevents oxidation of that substance) (<LINK REF="REF-Campos-1996" TYPE="REFERENCE">Campos 1996</LINK>). It is now accepted that the biological role of SOD is to scavenge superoxide, which is known to be generated in vivo after oxygen exposure (<LINK REF="REF-Fridovich-1995" TYPE="REFERENCE">Fridovich 1995</LINK>).<BR/>SOD is present in all eye tissues. The SOD activities of most eye tissues are largely inhibited by cianide and thus most activity can be attributed to CuZn-SOD. The retinal pigment epithelium additionally contains high levels of mitochondrial Mn-SOD (<LINK REF="REF-Evans-1995" TYPE="REFERENCE">Evans 1995</LINK>). Lens SOD can also be glycosylated in diabetes, causing loss of some enzymatic activity.<BR/>In May 1747, James Lind, a Scottish naval surgeon, probably conducted the first controlled clinical trial in medical history. He tested a variety of reputed remedies on 12 scorbutic sailors. Two of them were restricted to a control diet, but each of the others was additionally given one of the substances under trial. The two seamen who were provided with two oranges and a lemon each day made a speedy recovery. The only other sailors to show any signs of recovery were those who had been given cider. Lind observed no improvement in the condition of those who had been given either oil of vitriol, vinegar, sea-water (popular remedies for scurvy at the time) or just the control diet. But, surprisingly, it was not until 1795 that the British Admiralty finally agreed to Lind's demands for a regular issue of lemon juice on British ships (<LINK REF="REF-Nishikimi-1996" TYPE="REFERENCE">Nishikimi 1996</LINK>).<BR/>Ascorbic acid is present at high concentrations in the lens, cornea, retinal pigment epithelium, and aqueous humour of humans, monkeys and many other animals. Its ability to recycle &#945;-tocopheryl radical and scavenge superoxide, singlet oxygen, hydroxyl and other free radicals may be of importance, for example, in the treatment of diabetic retinopathy. Vitamin C readily scavenges reactive oxygen and nitrogen species, such as superoxide and hydroperoxyl radicals, aqueous peroxyl radicals, singlet oxygen, ozone, peroxy nitrite, nitrogen dioxide, nitroxide radicals, and hypochlorous acid (<LINK REF="REF-Carr-1999" TYPE="REFERENCE">Carr 1999</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-09-22 12:14:51 +0200" MODIFIED_BY="[Empty name]">
<P>Diabetic retinopathy is the most frequent cause of new cases of blindness among adults aged 20 to 74 years. That represents nearly all patients with type 1 diabetes and more than 60% of patients with type 2 diabetes (<LINK REF="REF-Fong-2003" TYPE="REFERENCE">Fong 2003</LINK>). This systematic review represents an attempt to offer novel ways of preventing or regressing the progression of diabetic retinopathy.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of vitamin C and superoxide dismutase for diabetic retinopathy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-11 13:48:19 +0100" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2008-11-08 10:55:44 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_STUDIES>
<P>We considered randomized clinical trials (RCTs) that evaluated the effect of vitamin C, superoxide dismutase or both on diabetic retinopathy.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We planned to include adult patients aged 20 to 75 years with diabetic retinopathy, detected clinically by the presence of visible ophthalmoscopic retinal microvascular lesions.</P>
<P>To be consistent with changes in classification and diagnostic criteria of diabetes mellitus through the years, the diagnosis should have been established using the standard criteria valid at the time of the beginning of the trial (for example <LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>; <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-WHO-1980" TYPE="REFERENCE">WHO 1980</LINK>; <LINK REF="REF-WHO-1985" TYPE="REFERENCE">WHO 1985</LINK>; <LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). Ideally, diagnostic criteria should have been described. If necessary, authors' definition of diabetes mellitus was planned to be used. The same applied to diagnostic criteria of diabetic retinopathy. Diagnostic criteria would be eventually subjected to a sensitivity analysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We considered the following types of intervention:<BR/>
</P>
<UL>
<LI>Vitamin C versus no treatment;</LI>
<LI>Vitamin C versus placebo;</LI>
<LI>Vitamin C versus photocoagulation;</LI>
<LI>Superoxide dismutase versus no treatment;</LI>
<LI>Superoxide dismutase versus placebo;</LI>
<LI>Superoxide dismutase versus photocoagulation;</LI>
<LI>Vitamin C and superoxide dismutase versus no treatment;</LI>
<LI>Vitamin C and superoxide dismutase versus placebo;</LI>
<LI>Vitamin C and superoxide dismutase versus photocoagulation. </LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-08 10:55:44 +0100" MODIFIED_BY="Gudrun Paletta">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-09-22 12:15:52 +0200" MODIFIED_BY="[Empty name]">
<P>We wanted to evaluate the efficacy of vitamin C and superoxide dismutase for diabetic retinopathy by considering the following endpoints:<BR/>
</P>
<UL>
<LI>progression of diabetic retinopathy;</LI>
<LI>incidence of blindness.</LI>
</UL>
<P>
<BR/>
</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-08 10:55:44 +0100" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>mortality (all-cause mortality; diabetes related mortality (death from myocardial infarction, stroke, peripheral vascular disease, renal disease, hyper- or hypoglycaemia or sudden death));</LI>
<LI>morbidity (all-cause morbidity as well as diabetes and cardiovascular related morbidity, for example angina pectoris, myocardial infarction, stroke, peripheral vascular disease, neuropathy, retinopathy, nephropathy, erectile dysfunction, amputation);</LI>
<LI>adverse effects;</LI>
<LI>health-related quality of life;</LI>
<LI>costs.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Covariates and effect modifiers</HEADING>
<UL>
<LI>duration of diabetes mellitus;</LI>
<LI>duration of diabetic retinopathy;</LI>
<LI>glycaemic control;</LI>
<LI>blood pressure control;</LI>
<LI>use of ACE inhibitors;</LI>
<LI>presence of other systemic diseases.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome assessment</HEADING>
<P>We planned to measure outcomes in medium and long term trials, depending on data.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-11 13:47:33 +0100" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-11 13:47:26 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We used the following sources for the identification of trials:<BR/>
</P>
<UL>
<LI>
<I>The Cochrane Library</I> (issue 2, 2006);</LI>
<LI>MEDLINE (until June 2006);</LI>
<LI>EMBASE (until October 2006);</LI>
<LI>CINAHL (until October 2006);</LI>
<LI>Web of Science (October 2006).</LI>
</UL>
<P>
<BR/>We also searched databases of ongoing trials: Current Controlled Trials (www.controlled-trials.com - with links to other databases of ongoing trials).</P>
<P>The described search strategy (see for a detailed search strategy under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> was used for MEDLINE. For use with EMBASE, <I>The Cochrane Library</I> and the other databases this strategy was slightly adapted.</P>
<P>Studies published in any language would be included.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-11 13:47:33 +0100" MODIFIED_BY="Gudrun Paletta">
<P>We contacted experts in order to identify unpublished research and trials still underway.</P>
<P>We tried to identify additional studies by searching the reference lists of included trials and (systematic) reviews, meta-analyses and health technology assessment reports noticed.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-11 13:48:19 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2008-11-11 13:48:19 +0100" MODIFIED_BY="Gudrun Paletta">
<P>To determine the studies to be assessed further, two authors (CCLJ and VFMT) independently scanned the abstract, titles or both sections of every record retrieved. All potentially relevant articles were investigated as full text. Interrater agreement for study selection was measured using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Differences were marked and if these studies were later on included, the influence of the primary choice would be subjected to a sensitivity analysis. Where differences in opinion existed, they were resolved by a third party. If resolving disagreement was not possible, the article was added to those 'awaiting assessment' and authors would be contacted for clarification. An adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection would be attached (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with duplicate publications</HEADING>
<P>In the case of duplicate publications and companion papers of a primary study, we would try to maximise yield of information by simultaneous evaluation of all available data. In cases of doubt, the original publication (usually the oldest version) would obtain priority.</P>
</SUBSECTION>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-09-22 12:21:07 +0200" MODIFIED_BY="[Empty name]">
<P>For studies that fulfilled inclusion criteria, two authors (CCLJ and VFMT) would independently abstract relevant population and intervention characteristics using standard data extraction templates with any disagreements to be resolved by discussion, or if required by a third party. Any relevant missing information on the trial would be sought from the original author(s) of the article, if required.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-09-22 12:21:27 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors (CCLJ and VFMT) would assess each trial independently. Possible disagreement would be resolved by consensus, or with consultation of a third party in case of disagreement. We planned to explore the influence of individual quality criteria in a sensitivity analysis (see under 'sensitivity analyses'). Interrater agreement for key quality indicators would be calculated using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). In cases of disagreement the rest of the group would be consulted and a judgement would be made based on consensus.</P>
<P>Additionally, we would assess the quality of reporting each trial based largely on the quality criteria specified by Schulz and Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). In particular, the following factors would be studied:<BR/>(1) Minimisation of selection bias: a) was the randomisation procedure adequate? b) was the allocation concealment adequate?<BR/>(2) Minimisation of performance bias: were the patients and people administering the treatment blind to the intervention?<BR/>(3) Minimisation of attrition bias: a) were withdrawals and dropouts completely described? b) was analysis by intention-to-treat?<BR/>(4) Minimisation of detection bias: were outcome assessors blind to the intervention?</P>
<P>Based on these criteria, studies would be broadly subdivided into the following three categories according to the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).<BR/>a) All quality criteria met: low risk of bias.<BR/>b) One or more of the quality criteria only partly met: moderate risk of bias.<BR/>c) One or more criteria not met: high risk of bias.</P>
</QUALITY_ASSESSMENT>
<MISSING_DATA MODIFIED="2008-11-11 13:48:11 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Relevant missing data would be obtained from authors, if feasible. Evaluation of important numerical data such as screened, eligible and randomised patients as well as intention-to-treat (ITT) and per-protocol (PP) population would be carefully performed. Attrition rates, for example drop-outs, losses to follow-up and withdrawals would be investigated. Issues of last-observation-carried-forward (LOCF), ITT and PP would be critically appraised and compared to specification of primary outcome parameters and power calculation.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-09-22 12:22:02 +0200" MODIFIED_BY="[Empty name]">
<P>In the event of substantial clinical or methodological or statistical heterogeneity, study results would not be combined by means of meta-analysis. Heterogeneity would be identified by visual inspection of the forest plots, by using a standard &#967;2-test and a significance level of &#945; = 0.1, in view of the low power of such tests. Heterogeneity would be specifically examined with I<SUP>2</SUP> (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>), where I<SUP>2</SUP> values of 50% and more indicate a substantial level of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I<SUP>2</SUP> demonstrates the percentage of total variation across studies due to heterogeneity and would be used to judge the consistency of evidence.<BR/>When heterogeneity was found, we would attempt to determine potential reasons for it by examining individual study characteristics and those of subgroups of the main body of evidence.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-09-22 12:22:14 +0200" MODIFIED_BY="[Empty name]">
<P>Funnel plots would be used in an exploratory data analysis to assess for the potential existence of small study bias. There are a number of explanations for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to study size, poor methodological design of small studies and publication bias (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). Thus, this exploratory data instrument might be misleading and we would not place undue emphasis on this tool (<LINK REF="REF-Lau-2006" TYPE="REFERENCE">Lau 2006</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-09-22 12:22:30 +0200" MODIFIED_BY="[Empty name]">
<P>Data would be summarised statistically if they were available, sufficiently similar and of sufficient quality. Statistical analysis would be performed according to the statistical guidelines referenced in the newest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-09-22 12:22:57 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup analyses would be mainly performed if one of the primary outcome parameters demonstrated statistically significant differences between intervention groups. In any other case subgroup analyses would be clearly marked as a hypothesis generating exercise.</P>
<P>The following subgroup analyses were planned:<BR/>
</P>
<UL>
<LI>gender;</LI>
<LI>geographical location of the study;</LI>
<LI>duration of diabetes mellitus;</LI>
<LI>diagnostic criteria for diabetes mellitus;</LI>
<LI>duration of diabetic retinopathy;</LI>
<LI>diagnostic criteria for diabetic retinopathy;</LI>
<LI>comparator strategy.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-09-22 12:23:37 +0200" MODIFIED_BY="[Empty name]">
<P>We would perform sensitivity analyses in order to explore the influence of the following factors on effect size:<BR/>
</P>
<UL>
<LI>repeating the analysis excluding unpublished studies;</LI>
<LI>repeating the analysis taking account of study quality, as specified above;</LI>
<LI>repeating the analysis excluding any very long or large studies to establish how much they dominate the results;</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>The robustness of the results would also be tested by repeating the analysis using different measures of effects size (relative risk, odds ratio etc.) and different statistical models (fixed and random effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-22 12:24:09 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-09-22 12:24:09 +0200" MODIFIED_BY="[Empty name]">
<P>We found no study which examined the treatment of diabetic retinopathy with vitamin C and superoxide dismutase.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Methodological quality was not evaluated because of the absence of studies about the treatment of diabetic retinopathy with vitamin C and superoxide dismutase.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>No research to date has examined the treatment of diabetic retinopathy with vitamin C and superoxide dismutase in such a way as to indicate whether the use of these substances has a significant impact on the progression of the disease or on the incidence of blindness. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>There is evidence of a key role of free radicals in the pathogenesis of diabetic retinopathy. The retina is high in polyunsaturated fatty acids and has the highest glucose oxidation and oxygen uptake of any tissue, thus being extremely susceptible to increased oxidative stress. Impaired activities of antioxidant defence enzymes (such as superoxide dismutase) appear to be one of the possible sources of oxidative stress in diabetes. Recent evidence also points to reactive oxygen species (ROS) in the mitogenic cascade initiated by the tyrosine kinase receptors of several growth factors including vascular endothelial growth factor (VEGF).<BR/>Antioxidants at least inhibit some retinal metabolic abnormalities and pathological changes induced by hyperglycemia. Therefore, it is reasonable to postulate that an antioxidative therapy may be useful to prevent the progression of diabetic retinopathy, combinations of drugs might be necessary to prevent vision loss in diabetic patients. Ascorbic acid is present at high concentrations in humans' eyes and its ability to scavenge reactive and oxygen species may be of importance in the treatment of diabetic retinopathy. Superoxide dismutase is present in all eye tissues. Its biological role is to scavenge superoxide, which is generated in vivo after oxygen exposure. The retinal pigment epithelium contains high levels of mitochondrial Manganese-Superoxide-Dismutase and a reduction in its level may be related to retinal lesion. Antioxidants, such as vitamin C and superoxide dismutase, may provide additional beneficial effects for patients with diabetic retinopathy. However, it appears that no clinical study with these substances has been performed so far. Since vitamin C and superoxide dismutase have the potential to positively influence diabetic eye disease these compounds should be investigated in RCTs on patient-oriented outcomes like incidence of blindness, progression of diabetic retinopathy, health-related quality of life and adverse effects of the treatment.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>In the absence of studies with potentially hopeful pharmacological treatments of diabetic retinopathy (such as vitamin C and superoxide dismutase), laser photocoagulation remains the primary treatment of this clinical condition. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Since laser photocoagulation is an invasive procedure which destroys retinal cells, novel approaches should be developed to prevent or regress retinal lesions in diabetic people. The role of free radicals in the pathogenesis of diabetic retinopathy and the potential therapeutic effects of vitamin C and superoxide dismutase in the treatment of diabetic eye disease remain open to debate. It is suggested that future research by means of sound RCTs concentrating on patient-oriented parameters should be performed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-22 12:34:06 +0200" MODIFIED_BY="[Empty name]">
<P>Conceiving the review: Carlos César Lopes de Jesus (CCLJ)<BR/>Designing the review: CCLJ, Virgínia Fernandes Moça Trevisani (VFMT)<BR/>Co-ordinating the review: Álvaro Nagib Atallah (ANA)<BR/>Undertaking manual searches: CCLJ, VFMT<BR/>Screening search results: CCLJ, VFMT<BR/>Organizing retrieval of papers: CCLJ, VFMT<BR/>Screening retrieved papers against inclusion criteria: CCLJ, VFMT<BR/>Appraising quality of papers: CCLJ, VFMT<BR/>Abstracting data from papers: CCLJ, VFMT<BR/>Writing to authors of papers for additional information: CCLJ<BR/>Providing additional data about papers: CCLJ<BR/>Obtaining and screening data on unpublished studies: CCLJ, VFMT<BR/>Data management for the review: CCLJ, VFMT<BR/>Entering data into Review Manager (RevMan 4.2): CCLJ, VFMT<BR/>Analysis of data: CCLJ, VFMT, Orsine Valente (OV)<BR/>Interpretation of data: CCLJ, OV, VFMT<BR/>Writing the review: CCLJ<BR/>Performing previous work that was the foundation of the present study: CCLJ<BR/>Guarantor for the review: VFMT<BR/>Statistical analysis: CCLJ, VFMT</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-03-25 12:12:48 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDIES MODIFIED="2009-03-25 11:51:10 +0100" MODIFIED_BY="Gudrun Paletta">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2009-03-25 11:51:10 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-Bandello-2003" NAME="Bandello 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bandello F, Pognuz R, Polito A, Pirracchio A, Menchini F, Ambesi M</AU>
<TI>Diabetic macular edema: classification, medical and laser therapy</TI>
<SO>Seminars in Ophthalmology</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>251-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caldwell-2005" NAME="Caldwell 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;. . 2005, 6: .&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell RB, Bartoli M, Behzadian MA, El Remessy AE, Al Shabrawey M, Platt DH et al</AU>
<TI>Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress</TI>
<SO>Current drug targets</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>511-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comer-2004" NAME="Comer 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comer GM, Ciulla TA,</AU>
<TI>Pharmacotherapy for diabetic retinopathy [erratuam appears in Curr Opin Ophthalmol 2005 Jun; 16(3): 195]</TI>
<SO>Current opinion in ophthalmology</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>508-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comer-2005" NAME="Comer 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comer GM, Ciulla TA</AU>
<TI>Current and future pharmacological intervention for diabetic retinopathy</TI>
<SO>Expert Opinion on Emerging Drugs</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>441-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunha_x002d_Vaz-1979" NAME="Cunha-Vaz 1979" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunha-Vaz JG, Faria DA, Jr., Fonseca JR</AU>
<TI>Studies on diabetic retinopathy. III</TI>
<SO>Management. Experientia Ophthalmologica</SO>
<YR>1979</YR>
<VL>5</VL>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunha_x002d_Vaz-2004" NAME="Cunha-Vaz 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunha-Vaz JG</AU>
<TI>Medical treatment of retinopathy of type2-diabetes</TI>
<SO>Ophthalmologica</SO>
<YR>2004</YR>
<VL>218</VL>
<PG>291-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-La-Cruz-2004" NAME="De La Cruz 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De La Cruz JP, Gonzalez-Correa JA, Guerrero A, De la Cuesta FS, et al</AU>
<TI>Pharmacological approach to diabetic retinopathy</TI>
<SO>Diabetes/metabolism research and reviews</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>91-113</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaede-2006" MODIFIED="2009-03-25 11:51:10 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Gaede 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-25 11:51:10 +0100" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaede PH</AU>
<TI>Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late diabetic complications</TI>
<SO>Danish Medical Bulletin</SO>
<YR>2006</YR>
<VL>53</VL>
<PG>258-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-2005" NAME="Gupta 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta MM, Chari S, Gupta MM, Chari S</AU>
<TI>Lipid peroxidation and antioxidant status in patients with diabetic retinopathy</TI>
<SO>Indian journal of physiology and pharmacology</SO>
<YR>2005</YR>
<VL>49</VL>
<PG>187-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ivanisevic-1994" NAME="Ivanisevic 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ivanisevic M</AU>
<TI>Present approach to medical therapy of diabetic retinopathy</TI>
<SO>Acta Clinica Croatica</SO>
<YR>1944</YR>
<VL>33</VL>
<PG>221-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jennings-1987" NAME="Jennings 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jennings PE, Chirico S, Jones AF, Lunec J, Barnett AH et al</AU>
<TI>Vitamin C metabolities and microangiopathy in diabetes mellitus</TI>
<SO>Diabetes research</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>151-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juhl-2004" NAME="Juhl 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juhl B</AU>
<TI>Vitamin C treatment reduces transcapillary escape rate of albumin in type 1 diabetes</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>428-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kowluru-2001" NAME="Kowluru 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kowluru RA, Kennedy A</AU>
<TI>Therapeutical potential of anti-oxidants and diabetic retinopathy</TI>
<SO>Expert opinion on investigational drugs</SO>
<YR>2001</YR>
<VL>10</VL>
<PG>1665-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leal-2005" NAME="Leal 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leal EC, Santiago AR, Ambrosio AF</AU>
<TI>Old and new drug targets indiabetic retinopathy: from biochemical changes to inflammation and neurodegeneration</TI>
<SO>Current drug targets. CNS and neurological disorders</SO>
<YR>2005</YR>
<VL>4</VL>
<PG>421-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mamputu-2004" NAME="Mamputu 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mamputu JC, Renier G</AU>
<TI>Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effects of antioxidants</TI>
<SO>Journal of Leukocyte Biology</SO>
<YR>2004</YR>
<VL>75</VL>
<PG>1062-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayer_x002d_Davis1998" NAME="Mayer-Davis1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF</AU>
<TI>Antioxidant nutrient intake and diabetic retinopathy: The San Luis Valley Diabetes Study</TI>
<SO>Ophthalmology</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>2264-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millen-2003" NAME="Millen 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millen AE, Gruber M, Klein R, Klein BEK, Palta M, Mares JA</AU>
<TI>Relations of serum ascorbic acid and a-tocopherol to diabetic retinopathy in the Third National Health and Nutrition Examination Survey</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2003</YR>
<VL>158</VL>
<PG>225-233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newport-2005" NAME="Newport 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newport A, Lockwood B</AU>
<TI>Use of nutraceuticals for eye health</TI>
<SO>Pharmaceutical Journal</SO>
<YR>2005</YR>
<VL>275</VL>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmieri-2006" NAME="Palmieri 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmieri B, Sblendorio V</AU>
<TI>Oxidative stress detection: what for? Part I</TI>
<SO>European Review for Medical &amp; Pharmacological Sciences</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>291-317</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porta-2004" NAME="Porta 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porta M, Allione A</AU>
<TI>Current approaches and perspectives in the medical treatment of diabetic retinopathy</TI>
<SO>Pharmacology &amp; Therapeutics</SO>
<YR>2004</YR>
<VL>103</VL>
<PG>167-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rema-1995" NAME="Rema 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rema M, Mohan V, Bhaskar A, Shanmugasundaram KR et al</AU>
<TI>Does antioxidant stress play a role in diabetic retinopathy?</TI>
<SO>Indian journal of ophthalmology</SO>
<YR>1995</YR>
<VL>43</VL>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sinclair-1992" NAME="Sinclair 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sinclair AJ, Girling AJ, Gray L, Lunec J, Barnett AH et al.</AU>
<TI>An investigation of the relationship between free radical activity and vitamin C metabolism in olderly diabetic subjects with retinopathy</TI>
<SO>Gerontology</SO>
<YR>1992</YR>
<VL>38</VL>
<PG>268-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soro_x002d_Paavonen-2006" NAME="Soro-Paavonen 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soro-Paavonen A, Forbes JM</AU>
<TI>Novel therapeutics for diabetic micro- and macrovascular complications</TI>
<SO>Current Medicinal Chemistry</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>1777-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinson-1994" NAME="Vinson 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinson J, Hsu C, Possanza C, Drack A, Pane D, Davis R et al</AU>
<TI>Lipid peroxidation and diabetic complications: effect of antioxidant vitamins C and E</TI>
<SO>Advances in experimental medicine and biology</SO>
<YR>1944</YR>
<VL>366</VL>
<PG>430-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" NAME="Wang 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X-F</AU>
<TI>Therapeutic methods of diabetic retinopathy and its molecular biological study</TI>
<SO>Zhongguo Lingchuan Kangfu</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>136-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wegewitz-2005" NAME="Wegewitz 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wegewitz U, Gohring I, Spranger J</AU>
<TI>Novel approaches in the treatment of angiogenic eye disease</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>2311-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yam-2007" NAME="Yam 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yam JC, Kwok AK, Yam JCS, Kwok AKH</AU>
<TI>Update on the treatment of diabetic retinopathy</TI>
<SO>Hong Kong medical journal</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>46-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yildirim-2007" NAME="Yildirim 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yildrim Z, Ucgun NI, Kilic N, Gursel E, Sepici-Dincel A et al</AU>
<TI>Antioxidant enzymes and diabetic retinopathy</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2007</YR>
<VL>1100</VL>
<PG>199-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-03-25 12:12:48 +0100" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_REFERENCES MODIFIED="2009-03-25 12:12:48 +0100" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-ADA-1997" NAME="ADA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20 Suppl 1</VL>
<PG>S5-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1999" NAME="ADA 1999" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</AU>
<TI>Report of the Expert Committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22 Suppl 1</VL>
<PG>S5-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balasubramanyam-2002" NAME="Balasubramanyam 2002" TYPE="JOURNAL_ARTICLE">
<AU>Balasubramanyam M, Rema M, Premanand C</AU>
<TI>Biochemical and molecular mechanisms of diabetic retinopathy</TI>
<SO>Current Science</SO>
<YR>2002</YR>
<VL>83</VL>
<PG>1506-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campos-1996" MODIFIED="2009-03-25 11:45:35 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Campos 1996" TYPE="BOOK_SECTION">
<AU>Campos S</AU>
<TI>Biomolecular medicine and free radicals</TI>
<TO>Medicina biomolecular e radicais livres</TO>
<YR>1996</YR>
<VL>1</VL>
<PG>137-43</PG>
<EN>1</EN>
<PB>Francolor Artes Gráficas e Editora Ltda</PB>
<CY>São Paulo</CY>
<MD>Press, BR1310.1 - Núcleo de Biblioteca</MD>
<IDENTIFIERS MODIFIED="2009-03-25 11:33:50 +0100" MODIFIED_BY="Gudrun Paletta"/>
</REFERENCE>
<REFERENCE ID="REF-Carr-1999" NAME="Carr 1999" TYPE="JOURNAL_ARTICLE">
<AU>Carr A C, Frei B</AU>
<TI>Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1999</YR>
<VL>6</VL>
<PG>1086 - 107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-1995" NAME="Evans 1995" TYPE="JOURNAL_ARTICLE">
<AU>Evans PJ</AU>
<TI>Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis</TI>
<SO>Free Radicals Residence</SO>
<YR>1995</YR>
<VL>23</VL>
<PG>465</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fong-2003" NAME="Fong 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD et al</AU>
<TI>Diabetic retinopathy</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>99 - 102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fridovich-1995" NAME="Fridovich 1995" TYPE="JOURNAL_ARTICLE">
<AU>Fridovich I</AU>
<TI>Superoxide radical and superoxide dismutases</TI>
<SO>Annual Review of Biochemistry</SO>
<YR>1995</YR>
<VL>64</VL>
<PG>97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-1984" NAME="Klein 1984" TYPE="JOURNAL_ARTICLE">
<AU>Klein R, Klein BE, Mors SE, Davis MD, DeMets DL</AU>
<TI>The Wisconsin Epidemiologic Study of Diabetic Retinopathy</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1984</YR>
<VL>102</VL>
<NO>4</NO>
<PG>532-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-2006" NAME="Lau 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I</AU>
<TI>The case of the misleading funnel plot</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nishikimi-1996" NAME="Nishikimi 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nishikimi M, Yagi K</AU>
<TI>Biochemistry and molecular biology of ascorbic acid biosybthesis</TI>
<SO>Subcellular Biochemistry</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JAC, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<PG>1046-1055</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1980" NAME="WHO 1980" TYPE="OTHER">
<AU>WHO Expert Committee on Diabetes Mellitus</AU>
<TI>Second report. Technical Report Series 646</TI>
<SO>Geneva. WHO, 1980</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1985" NAME="WHO 1985" TYPE="OTHER">
<TI>WHO Expert Committee on Diabetes Mellitus</TI>
<SO>World Health Organization, 1985. Technical Report Series 727</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" NAME="WHO 1998" TYPE="JOURNAL_ARTICLE">
<AU>Alberti KM, Zimmet PZ</AU>
<TI>Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<PG>539-53</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bandello-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caldwell-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Comer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Comer-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cunha_x002d_Vaz-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cunha_x002d_Vaz-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-La-Cruz-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaede-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study about a multifactorial intervention in patients with type 2 diabetes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gupta-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>In this study, oxidative stress as measured by the levels of malondialdehyde, superoxide dismutase, glutathione peroxidase and vitamin C was measured in 50 normal controls, 40 diabetics without complications, 22 diabetics with proliferative and 20 with nonproliferative retinopathy respectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ivanisevic-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jennings-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigated ascorbic and dehydroascorbic acids concentrations in diabetics and matched normal controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Juhl-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study describes a reduction in transcapillary escape rate of albumin in type-1 diabetes patients treated with vitamin C.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kowluru-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leal-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mamputu-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Authors examined the in vitro effect of advanced glycosylated endproducts on human monocyte adhesion to bovine endothelial cells and the molecular mechanisms involved in this effect.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mayer_x002d_Davis1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Epidemiological study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Millen-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Epidemiological study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Newport-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study about age-related macular degeneration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Palmieri-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Porta-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rema-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Epidemiological study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sinclair-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study measured free radical activity using thiobarbituric acid, malonyldialdehyde and reduced glutathione.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Soro_x002d_Paavonen-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vinson-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study investigated the beneficial effects of vitamin C and E upon sorbitol, glycation and lipid peroxidation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wegewitz-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yam-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yildirim-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study investigated the correlation of serum copper, zinc, nitric oxide, glutathione, advanced oxidation protein products and superoxide dismutase with diabetic retinopathy severity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-22 12:42:17 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-22 12:42:25 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-09-22 12:19:37 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-22 12:18:33 +0200" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-22 12:19:37 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.</P>
<P/>
<P>
<B>MEDLINE:</B>
</P>
<P>1 exp Diabetic Retinopathy/<BR/>2 exp Retinal Detachment/<BR/>3 exp Retinal Degeneration/<BR/>4 exp retinal hemorrhage/ or exp retinal neovascularization/ or exp vitreoretinopathy, proliferative/<BR/>5 vitreous detachment/ or vitreous hemorrhage/<BR/>6 (eye diseas$ or blindness or visual loss$ or vitrectom$ or cataract$).ti.<BR/>7 retina$ detachment$.ti,ab.<BR/>8 vitreous haemorrhag$.ti,ab.<BR/>9 vitreous hemorrhag$.ti,ab.<BR/>10 (macular adj (oedema or edema)).ti,ab.<BR/>11 microaneurysm$.ti,ab.<BR/>12 neovascular$.ti,ab.<BR/>13 fibrous tissue$.ti,ab.<BR/>14 (retinopath$ or retinitis or maculopath$).ti.<BR/>15 (macula defect$ or macula degeneration$).ti.<BR/>16 (macula$ adj (defect$ or degeneration$)).ti,ab.<BR/>
<BR/>17 or/2-16<BR/>
<BR/>18 exp diabetes mellitus/<BR/>19 diabet$.tw.<BR/>20 IDDM.tw.<BR/>21 NIDDM.tw.<BR/>22 MODY.tw.<BR/>23 (maturity onset adj diabet$).tw.<BR/>24 hyperinsulin$.tw.<BR/>25 insulin sensitiv$.tw.<BR/>26 insulin$ resist$.tw.<BR/>27 (non insulin$ depend$ or noninsulin$ depend$ or non insulin?depend$ or<BR/>noninsulin?depend$).tw.<BR/>28 ((typ$ 1 or typ$ 2) and diabet$).tw.<BR/>29 ((typ$ I or typ$ II) and diabet$).tw.<BR/>30 exp Insulin Resistance/<BR/>31 (insulin$ depend$ or insulin?depend$).tw.<BR/>
<BR/>32 or/18-31<BR/>
<BR/>33 17 and 32<BR/>34 1 or 33<BR/>
<BR/>35 exp Ascorbic Acid/<BR/>36 exp Antioxidants/tu [Therapeutic Use]<BR/>37 Vitamin$ C.tw.<BR/>38 ascorbic acid.tw.<BR/>39 SOD.tw.<BR/>40 exp Superoxide Dismutase/<BR/>41 superoxide dismutase.tw.<BR/>42 (antioxidant adj6 (drug$ or therap$ or treatment$)).tw.<BR/>43 (anti adj6 oxidants).tw.<BR/>44 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43<BR/>
<BR/>45 34 and 44<BR/>
<BR/>46 randomized controlled trial.pt.<BR/>47 controlled clinical trial.pt.<BR/>48 randomized controlled trials.sh.<BR/>49 random allocation.sh.<BR/>50 double-blind method.sh.<BR/>51 single-blind method.sh.<BR/>52 46 or 47 or 48 or 49 or 50 or 51<BR/>53 limit 52 to animal<BR/>54 limit 52 to human<BR/>
<BR/>55 53 not 54<BR/>56 52 not 55<BR/>
<BR/>57 clinical trial.pt.<BR/>58 exp clinical trials/<BR/>59 (clinic$ adj25 trial$).tw.<BR/>60 ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.<BR/>61 placebos.sh.<BR/>62 placebo$.tw.<BR/>63 random$.tw.<BR/>64 research design.sh.<BR/>65 (latin adj square).tw.<BR/>66 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65<BR/>67 limit 66 to animal<BR/>68 limit 66 to human<BR/>
<BR/>69 67 not 68<BR/>70 66 not 69<BR/>
<BR/>71 comparative study.sh.<BR/>72 exp evaluation studies/<BR/>73 follow-up studies.sh.<BR/>74 prospective studies.sh.<BR/>75 (control$ or prospectiv$ or volunteer$).tw.<BR/>76 cross-over studies.sh.<BR/>77 71 or 72 or 73 or 74 or 75 or 76<BR/>78 limit 77 to animal<BR/>79 limit 77 to human<BR/>
<BR/>80 78 not 79<BR/>81 77 not 80<BR/>82 56 or 70 or 81<BR/>83 45 and 82<BR/>
</P>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P>
<BR/>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>